Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. From Wikipedia
The decision follows reports of severe complications and deaths among patients, prompting regulatory reviews and impacting the market.
